Summary
U C B has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €9.16bn and a net result of €383.4m. Equity remains stable across the filed financial years (±1.2% per year). Its solvency ranks better than 73% of 1,156 sector peers (NACE 82, financial year 2025). The company has been active since 1925 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
36 holdings · 45 subsidiaries in the treeHoldings 36
-
100%
-
100%
-
100%
-
100%
-
100%
-
100%
-
100%
-
100%
-
100%
-
100%
Show 26 more holdings
-
100%
-
100%
-
100%
- UCB Pharmaceuticals (Taiwan) LtdCNsubsidiarySourceown accounts 2025Equity TWD 110.7mResult TWD 20.3m100%
-
100%
-
100%
-
100%
-
99.99%
- UCB PHARMAsubsidiaryEquity €17.19bnResult €4.09bn99.99%
- UCB VenturessubsidiaryEquity €249.8mResult €1.8m99.99%
-
99.97%
-
99.9%
-
99.85%
- UCB Pharma (Produtos Farmacêuticos) LdaPTsubsidiarySourceown accounts 2025Equity €5.3mResult €927,85798.33%
-
97.82%
-
78.05%
-
77.83%
- UCB BelgiumsubsidiarySourceLEI registerconsolidated
- UCB BIOPHARMAsubsidiarySourceLEI registerconsolidated
- UCB FINANCE N.V.NLsubsidiarySourceLEI registerconsolidated
- UCB FiparsubsidiarySourceLEI registerconsolidated
- UCB MANUFACTURING IRELAND LIMITEDIEsubsidiarySourceLEI registerconsolidated
- UCB PHARMA LIMITEDGBsubsidiarySourceLEI registerconsolidated
- UCB Ventures BelgiumsubsidiarySourceLEI registerconsolidated
- ZOGENIX INTERNATIONAL LIMITEDGBsubsidiarySourceLEI registerconsolidated
-
5.21%
All subsidiaries, including indirect ones 45
Companies in which this company or one of its subsidiaries holds more than half, or which it consolidates according to the LEI register.
- UCB (Pharma) Ireland LTDIE 100%
- UCB Bulgaria EOODBG 100%
- UCB DE MEXICO S.A. de C.V.MX 100%
- UCB HUNGARY LTDHU 100%
- UCB Japan Co LTDJP 100%
- UCB Korea Co LTDKP 100%
- UCB Manufacturing Ireland Ltd.IE 100%
- UCB Pharma A.S. (TURKEY)TR 100%
- UCB Pharma France SASFR 100%
- UCB Pharma LLC (Russia)RU 100%
- UCB Pharma Logistics LLCRU 100%
- UCB Pharma Romania SRLRO 100%
- UCB Pharma S.A. (Spain)ES 100%
- UCB Pharmaceuticals (Taiwan) LtdCN 100%
- UCB S.R.O.CZ 100%
- UCB Trading (Shanghai) Ltd.CN 100%
- Vedim Sp. z.o.o.PL 100%
- UCB Biopharma S.A.BR 99.99%
UCB PHARMA 99.99%10 subsidiaries
- UCB Farchim SA (AG - Ltd)CH 100%
- UCB Holdings, Inc.US 100%
- UCB Nordic ASDK 100%
- UCB Pharma A.S.NO 100%
- UCB Pharma AbSE 100%
- UCB Pharma B.V.NL 100%
- UCB Pharma GmbH AustriaAT 100%
- UCB Pharma OyFI 100%
- UCB GmbHDE 94.79%
- UCB PHARMA GMBHDE consolidated
- UCB Ventures 99.99%
- UCB India Private LtdIN 99.97%
- UCB Pharma S.P.A. (Italy)IT 99.9%
- UCB A.E. (Greece)GR 99.85%
- UCB Pharma (Produtos Farmacêuticos) LdaPT 98.33%
- UCB (Investments) LTDGB 97.82%
- UCB Pharma Sp. z.o.o. (Poland)PL 78.05%
- UCB Australia Pty. LTDAU 77.83%
- UCB Belgium consolidated
- UCB BIOPHARMA consolidated
- UCB FINANCE N.V.NL consolidated
- UCB Fipar consolidated
- UCB MANUFACTURING IRELAND LIMITEDIE consolidated
- UCB PHARMA LIMITEDGB consolidated
- UCB Ventures Belgium consolidated
- ZOGENIX INTERNATIONAL LIMITEDGB consolidated
According to the 2025 annual accounts of U C B and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.